Aptamer strikes new development contract agreement

Aptamer said on Thursday that the contract focuses on developing two Optimer binders as critical reagents for therapeutic monitoring.

The AIM-listed group also noted that upon successful development, Aptamer could receive "a significant undisclosed IP transfer fee" for the use of the Optimers in clinical trial monitoring.

Chief executive Dr Arron Tolley said: "This agreement further demonstrates our strategic model of leveraging fee-for-service revenue for the development of Optimer binders and potential licensing revenues.

"With a healthy pipeline and increasing traction among both new and repeat customers, we are demonstrating our commercial strategy. These advancements align with our broader vision of driving shareholder value by pairing fee-for-service income with scalable licensing opportunities."

As of 1015 GMT, Aptamer shares were up 6.67% at 0.40p.

Reporting by Iain Gilbert at Sharecast.com